Martins Pedro, Jesus João, Santos Sofia, Raposo Luis R, Roma-Rodrigues Catarina, Baptista Pedro Viana, Fernandes Alexandra R
UCIBIO, Departamento de Ciências da Vida, Faculdade de Ciências e Tecnologia da Universidade Nova de Lisboa, Campus de Caparica, 2829-516 Caparica, Portugal.
Centro de Química Estrutural, Complexo 1, Instituto Superior Técnico, Universidade de Lisboa, Av. Rovisco Pais, 1049-001 Lisboa, Portugal.
Molecules. 2015 Sep 16;20(9):16852-91. doi: 10.3390/molecules200916852.
The majority of heterocycle compounds and typically common heterocycle fragments present in most pharmaceuticals currently marketed, alongside with their intrinsic versatility and unique physicochemical properties, have poised them as true cornerstones of medicinal chemistry. Apart from the already marketed drugs, there are many other being investigated for their promising activity against several malignancies. In particular, anticancer research has been capitalizing on the intrinsic versatility and dynamic core scaffold of these compounds. Nevertheless, as for any other promising anticancer drugs, heterocyclic compounds do not come without shortcomings. In this review, we provide for a concise overview of heterocyclic active compounds and families and their main applications in medicine. We shall focus on those suitable for cancer therapy while simultaneously addressing main biochemical modes of action, biological targets, structure-activity relationships as well as intrinsic limitation issues in the use of these compounds. Finally, considering the advent of nanotechnology for effective selective targeting of drugs, we shall discuss fundamental aspects and considerations on nanovectorization of such compounds that may improve pharmacokinetic/pharmacodynamic properties of heterocycles.
大多数杂环化合物以及目前市面上大多数药物中常见的典型杂环片段,凭借其固有的多功能性和独特的物理化学性质,已成为药物化学的真正基石。除了已上市的药物外,还有许多其他药物正在针对多种恶性肿瘤进行有前景的活性研究。特别是,抗癌研究一直在利用这些化合物固有的多功能性和动态核心骨架。然而,与任何其他有前景的抗癌药物一样,杂环化合物并非没有缺点。在本综述中,我们简要概述了杂环活性化合物及其家族以及它们在医学中的主要应用。我们将重点关注那些适用于癌症治疗的化合物,同时探讨其主要生化作用模式、生物学靶点、构效关系以及使用这些化合物时的内在局限性问题。最后,考虑到纳米技术可实现药物的有效选择性靶向,我们将讨论此类化合物纳米载体制备的基本方面和注意事项,这可能会改善杂环化合物的药代动力学/药效学性质。